UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13
or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 15, 2005
Senomyx, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-50791 |
|
33-0843840 |
|
(State or other
jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
|
|
|
|
|
|
11099
North Torrey Pines Road |
|
92037 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
|
|
||||
|
Registrant’s telephone number, including area code: (858) 646-8300 |
||||
|
|
||||
|
Not Applicable. |
||||
|
(Former name or former address, if changed since last report.) |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 15, 2005 we entered into a Collaborative Research and License Agreement with Cadbury Adams USA, LLC for the discovery and commercialization of new flavor ingredients in the gum confectionary area. Under the terms of the agreement, Cadbury has agreed to pay us research funding for up to two years based on research progress during the collaborative period. In addition, we are eligible to receive milestone payments upon achievement of specific product discovery and development goals. The combined total of research funding and milestone payments could exceed $3 million if all milestones are met. Upon commercialization, we will receive royalty payments based on sales of products containing new flavor ingredients developed under the agreement.
The press release dated July 18, 2005 announcing our entry into the agreement and describing certain of its material terms is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press release of Senomyx, Inc. dated July 18, 2005.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
SENOMYX, INC. |
||
|
|
|
|
||
|
|
|
By: |
/s/ HARRY J. LEONHARDT, ESQ. |
|
|
|
|
|
Harry J. Leonhardt, Esq. |
|
|
|
|
|
Vice President, General Counsel and |
|
Date: July 18, 2005
3
INDEX TO EXHIBITS
99.1 Press release of Senomyx, Inc. dated July 18, 2005.
4